Can the CSL share price growth be repeated?

The CSL Limited (ASX: CSL) share price is up more than 40,000% since its IPO, but could we see even more growth in 2020 and beyond?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has surged 17.81% higher in 2020 to $324.86 per share.

For context, CSL listed in 1994 for a stock-split-adjusted price of just $0.76 per share. That means shares in the ASX biotech giant are up a whopping 42,633.74% since listing.

Incredibly, a $10,000 investment in the CSL IPO would now be worth over $4.2 million.

But can the Aussie biotech giant really repeat its astronomical share price growth?

Why CSL shares have rocketed higher in recent years

It's been an impressive ascendancy for the CSL share price in recent times. As of right now, the biotech group is the largest ASX company by market capitalisation and is worth nearly $150 billion.

There are many reasons why CSL has gone on to be as successful as it is today. The group's focus on research and development has certainly paid dividends for the company and its shareholders.

A combination of that R&D, strategic acquisitions and strong earnings growth have been critical to the group's success.

It would be almost unheard of for the CSL share price to rocket thousands of percent higher from here. However, stranger things have happened.

The Aussie biotech group continues to innovate and looks to be a good defensive buy in the coronavirus-induced bear market.

Shares in the group have outperformed the S&P/ASX 200 Index (ASX: XJO) by quite a margin in 2020. 

CSL shares are yielding just 0.90% right now. Given the likely dividend cuts we're going to see in 2020, that's not a bad thing.

However, I also expect CSL to go from a growth focus to a dividend focus in the coming years. That could be good news for income investors who want to own a piece of the biotech group and still receive some handy payouts.

Foolish takeaway

If CSL does pivot towards being a higher dividend-paying share, that means the CSL share price growth is unlikely to be repeated anytime soon.

However, if the R&D pipeline remains strong and management continue to deliver innovative biotechnology solutions, anything is possible.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »